Ocrevus (ocrelizumab) works by depleting a type of immune cell called B cells, and stopping the drug doesn’t immediately reverse that effect. Most people retain significant protection from MS disease activity for roughly two to two and a half years after their last infusion. After that point, the risk of relapses and new brain lesions starts climbing as B cells repopulate and the immune system regains the ability to attack nerve tissue.
How Long the Drug’s Effects Last
Ocrevus has a terminal half-life of 26 days, meaning the drug itself clears from your blood within a few months. But because it works by wiping out B cells rather than just suppressing them temporarily, the therapeutic effect outlasts the drug’s physical presence by a wide margin.
B-cell recovery follows a slow, predictable curve. At six months after the last infusion, only about 3 to 5 percent of patients show meaningful B-cell repopulation. By nine months, roughly half have recovered at least some B cells. By 12 months, 85 to 90 percent have. In a clinical study of 51 patients, the median time for B-cell counts to fully return to baseline was 72 weeks (about a year and a half), and 90 percent of patients reached baseline within two and a half years.
This long tail of immune suppression is why disease activity doesn’t typically return right away. It also means your immune system remains partially compromised for months after stopping, which matters for things like vaccine responses and infection risk.
When Disease Activity Returns
A study published in the Journal of Neurology, Neurosurgery & Psychiatry tracked patients who discontinued ocrelizumab and found that disease activity stayed stable for roughly 24 to 30 months after the last infusion. Beyond that window, protection eroded noticeably.
In that study, 10 percent of patients experienced clinical relapses after stopping. Another 7 percent developed new lesions visible on MRI without experiencing noticeable symptoms. The sharpest inflection point appeared around 32 months off treatment: after that mark, the risk of both clinical relapses and new MRI lesions rose substantially.
The important takeaway is that stopping Ocrevus doesn’t trigger an immediate crisis for most people. You have a buffer period of roughly two years where B-cell levels remain low enough to keep MS suppressed. But the disease hasn’t gone away. Once the immune system rebuilds, it can resume attacking the protective coating around nerve fibers.
No Rebound Effect, but Still a Risk
Some MS drugs, particularly natalizumab, are known for causing a “rebound effect” where disease activity comes roaring back worse than before treatment once the drug is stopped. Ocrevus does not appear to cause this kind of rebound. The return of disease activity after discontinuation looks more like a gradual loss of protection than an explosive flare.
That said, the absence of rebound doesn’t mean stopping is risk-free. The 10 percent relapse rate in the discontinuation study is a real number, and new lesions can accumulate silently. Some of the damage MS causes is irreversible, so even a modest return of disease activity matters over time. If you’re considering stopping, regular MRI monitoring is the most reliable way to catch new activity before it causes lasting harm.
Switching to a Different Treatment
Many people who stop Ocrevus aren’t abandoning MS treatment entirely. They’re switching to a different medication, sometimes due to side effects, infection concerns, or a desire to try a less immunosuppressive option. French Multiple Sclerosis Society guidelines recommend a three-month washout period after ocrelizumab before starting another high-potency therapy. Switching to a milder, first-line treatment can sometimes be done without waiting, depending on the specific drug.
The timing matters because starting a new immune-targeting therapy while B cells are still deeply depleted can compound the immunosuppression and raise infection risk. Your neurologist will typically check B-cell levels or wait a set interval before initiating the next medication.
Pregnancy Planning After Ocrevus
Pregnancy is one of the most common reasons people deliberately stop Ocrevus. The drug’s labeling recommends waiting 6 to 12 months after the last infusion before trying to conceive. However, recent expert guidelines have shifted toward a shorter timeline, with some neurologists advising that conception attempts can begin as early as the next menstrual cycle after the most recent infusion.
The rationale for the shorter wait is that pregnancy itself has a protective effect against MS relapses, particularly in the second and third trimesters. Combined with the lingering B-cell depletion from Ocrevus, many women remain well-protected through pregnancy even without active treatment. The postpartum period carries higher relapse risk, however, and restarting treatment after delivery is a conversation worth having with your neurologist before you conceive.
Why Some People Stop
People discontinue Ocrevus for a range of reasons: repeated infections, concern about long-term immune suppression, stable disease that makes them question whether they still need aggressive treatment, insurance or cost barriers, or life events like pregnancy. Some older patients with progressive MS and no recent disease activity choose to stop because the risks of ongoing immunosuppression (particularly serious infections) may begin to outweigh the benefits in later life.
Whatever the reason, the decision isn’t all-or-nothing. The slow pace of B-cell recovery gives you and your neurologist time to monitor for any signs of returning disease activity and adjust course if needed. The key numbers to remember: protection holds reasonably well for about two years, the risk inflection point sits around 32 months, and full B-cell recovery takes up to two and a half years for most people.